Frédéric Revah
Amministratore Delegato presso Genethon
Profilo
Frédéric Revah is currently the Chief Executive Officer at Genethon since 2010.
He is also the Chairman at Atamyo Therapeutics SAS and a Member-Management Board at Hera Diagnostics SAS.
Previously, he served as the Chief Executive Officer at Sepal Pharma SA in 2011.
He was also the Chairman at Yposkesi and a Director at Eurofins-Cerep SA. Dr. Revah started his career at Sanofi as the Head-Gene Therapy Department from 1992 to 1998.
He holds an undergraduate degree from Ecole Polytechnique, which he obtained in 1985, and a doctorate degree from Université de Paris 5 René Descartes, which he received in 1991.
Posizioni attive di Frédéric Revah
| Società | Posizione | Inizio |
|---|---|---|
Genethon
 Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Amministratore Delegato | 01/01/2010 |
| Hera Diagnostics SAS | Corporate Officer/Principal | 14/03/2011 |
Atamyo Therapeutics SAS
 Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | Presidente | - |
Precedenti posizioni note di Frédéric Revah
| Società | Posizione | Fine |
|---|---|---|
Yposkesi
 Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Presidente | 01/04/2021 |
| SANOFI | Corporate Officer/Principal | 01/01/1998 |
| EUROFINS CEREP | Direttore/Membro del Consiglio | - |
Sepal Pharma SA
 Sepal Pharma SA Pharmaceuticals: MajorHealth Technology Sepal Pharma SA develops cancer therapies. The company was founded on July 20, 2004 and is headquartered in Paris, France. | Amministratore Delegato | - |
Formazione di Frédéric Revah
| Ecole Polytechnique | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SANOFI | Health Technology |
| EUROFINS CEREP | Commercial Services |
| Aziende private | 6 |
|---|---|
Sepal Pharma SA
Sepal Pharma SA Pharmaceuticals: MajorHealth Technology Sepal Pharma SA develops cancer therapies. The company was founded on July 20, 2004 and is headquartered in Paris, France. | Health Technology |
| Université de Paris 5 René Descartes | Consumer Services |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Health Technology |
| Hera Diagnostics SAS | |
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Health Technology |
Atamyo Therapeutics SAS
Atamyo Therapeutics SAS BiotechnologyHealth Technology Atamyo Therapeutics SAS is a clinical-stage biopharmaceutical company based in France. Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon, a spin-off of gene therapy pioneer Genethon. Atamyo's most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage programs targeting respectively LGMD-R9 and LGMD-R5. The name of the French company is derived from two words\: Celtic Atao which means "always" or "forever" and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments. Atamyo brings to patients with musculoskeletal diseases a new generation of gene therapies with enhanced safety and efficacy. The private company was founded in 2020 by Stéphane Degove and Isabelle Richard. Stéphane Degove has been the CEO since 2020. | Health Technology |
- Borsa valori
- Insiders
- Frédéric Revah
